JLPC(SH:600513) Jin Rong Jie·2025-08-21 06:59Group 1 - The stock of Lianhuan Pharmaceutical experienced a significant drop, closing at 25.91 yuan, down 2.88 yuan or 10.00% from the previous trading day, with over 28,521 sell orders waiting, indicating nearly 74 million yuan in funds attempting to exit [1] - Lianhuan Pharmaceutical's stock had previously surged by 240.67% from June 24 to August 20, reaching a peak price of 31.58 yuan, highlighting the adjustment pressure following such a substantial increase [2][4] - The market speculation around Lianhuan Pharmaceutical is primarily driven by its innovative drug project LH-1801, which targets a large market for diabetes treatment, directly competing with AstraZeneca's Dapagliflozin, projected to generate 7.7 billion USD in global sales by 2024 [4] Group 2 - The company announced a projected loss of 38 to 45 million yuan for the first half of 2025, a shift from profit to loss, mainly due to monopoly fines and losses from subsidiaries [4] - Lianhuan Pharmaceutical faced a fine of 61.04 million yuan for monopolistic practices related to the price of Dexamethasone phosphate raw materials, which accounts for 72.53% of the projected net profit for 2024 [4] - The company's main business segments include tablets, medical devices, raw materials, and injections, contributing 49.32%, 24.8%, 12.95%, and 4.02% to total revenue, respectively [4]